



FOR IMMEDIATE RELEASE

CONTACT:

Nick Wasmiller

SeyferthPR

1-800-435-9539

wasmiller@seyferthpr.com

METABOLIC SOLUTIONS DEVELOPMENT COMPANY TO PRESENT RESEARCH FINDINGS TO EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

Research shows that company's clinical candidate promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat

KALAMAZOO, MICH. (Sept. 16, 2010) – Metabolic Solutions Development Company (MSDC), www.msdrx.com, will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010. The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat. The research was conducted in tissue cultures and mice.

[Numerous scientific studies](#) have shown that the amount of brown adipose tissue (commonly known as "brown fat") in the human body is an important factor in determining if calories are burned as energy or stored as fat.

"Lean people have more brown fat than individuals who are obese," said Jerry Colca, president and chief scientific officer of MSDC. "The amount of brown fat in the body decreases as an individual ages, particularly in men. If a person had more brown fat, that individual would be better able to lose weight."

"Our clinical candidates (including MSDC-0160) promote the proliferation of brown fat tissue from stem cells through cellular differentiation," said Rolf Kletzien, senior MSDC author on the study. "The ability of our clinical candidates to activate a novel biochemical pathway may provide additional insight and understanding into the

mechanism by which they lower blood glucose in human patients without causing weight gain.”

Pharmaceuticals that impact a human’s ability to produce brown fat may provide a new means to treat diseases related to excess body weight and cardiometabolic syndrome.

MSDC is a drug development company that is creating and testing a series of pharmaceutical candidates designed to treat type 2 diabetes more effectively without the side effects of current therapies.

An MSDC Phase 2a clinical trial of MSDC-0160 demonstrated that it improves insulin sensitivity and lowers blood glucose levels in humans without the side effects of the current market-leading diabetes medicines. The compound also demonstrated significant improvements in other important metabolic disease risk factors including blood pressure and lipids.

###

About Metabolic Solutions Development Company:

Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.

The company’s scientific strategy is built on a historical understanding of insulin-sensitizers and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.